| Literature DB >> 32418772 |
Fabio Facchinetti1, Maria Salome Bezerra Espinola2, Didier Dewailly3, Ali Cenk Ozay4, Nikos Prapas5, Mónica Vazquez-Levin6, Artur Wdowiak7, Vittorio Unfer8.
Abstract
It is well known that myo-inositol (MI) and D-chiro-inositol (DCI) are insulin-sensitizing agents, and MI is of proven utility in polycystic ovary syndrome (PCOS). In addition, MI plays a pivotal role in the physiology of reproduction, and has beneficial effects on the development of oocytes, spermatozoa, and embryos. By contrast, DCI has little effect on spermatozoa, but high concentrations in the ovary can negatively affect the quality of oocytes and the blastocyst. Overall, the evidence in the literature supports the beneficial effects of MI in both female and male reproduction, warranting clinical use of MI in assisted reproductive treatment (ART).Entities:
Keywords: D-chiro-inositol, polycystic ovary syndrome; assisted reproductive treatment; in vitro fertilization; infertility; myo-inositol
Mesh:
Substances:
Year: 2020 PMID: 32418772 DOI: 10.1016/j.tem.2020.04.003
Source DB: PubMed Journal: Trends Endocrinol Metab ISSN: 1043-2760 Impact factor: 12.015